Customize your JAMA Network experience by selecting one or more topics from the list below.
Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-Controlled Transdermal Fentanyl Hydrochloride vs Intravenous Morphine Pump for Postoperative Pain: A Randomized Controlled Trial. JAMA. 2004;291(11):1333–1341. doi:10.1001/jama.291.11.1333
Author Affiliations: Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pa (Dr Viscusi); Loma Linda University–Center for Pain Management, Loma Linda, Calif (Dr Reynolds); Department of Anesthesiology, University of Toronto, Toronto Western Hospital, Ontario (Dr Chung); Statistics and Data Management (Dr Khanna) and Clinical Development (Dr Atkinson), ALZA Corporation, Mountain View, Calif.
Context Patient-controlled analgesia (PCA) with morphine is commonly used to
provide acute postoperative pain control after major surgery. The fentanyl
hydrochloride patient-controlled transdermal system eliminates the need for
venous access and complicated programming of pumps.
Objective To assess the efficacy and safety of an investigational patient-controlled
iontophoretic transdermal system using fentanyl hydrochloride compared with
a standard intravenous morphine patient-controlled pump.
Design, Setting, and Patients Prospective randomized controlled parallel-group trial conducted between
September 2000 and March 2001 at 33 North American hospitals, enrolling 636
adult patients who had just undergone major surgery.
Interventions In surgical recovery rooms, patients were randomly assigned to intravenous
morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient-controlled
analgesia pump (n = 320) or iontophoretic fentanyl hydrochloride (40-µg
infusion over 10 minutes) by a patient-controlled transdermal system (n =
316). Supplemental analgesia (morphine or fentanyl intravenous boluses) was
administered as needed before and for the first 3 hours after activation of
the PCA treatments. Patients then used the PCA treatments without additional
analgesics for up to 72 hours.
Main Outcome Measures The primary efficacy variable was patient global assessment of the method
of pain control during the first 24 hours. Additional efficacy measures were
the proportion of patients discontinuing the study because of inadequate analgesia
for any reason, patient-reported pain intensity scores on a 100-mm visual
analog scale (VAS), and patient global assessments at 48 and 72 hours. Adverse
effects were also recorded.
Results Ratings of good or excellent after 24 hours of treatment for the method
of pain control were given by 73.7% of patients (233/316) who used transdermal
fentanyl PCA and 76.9% of patients (246/320) who used intravenous morphine
PCA; treatment difference was –3.2% (95% confidence interval, –9.9%
to 3.5%; P = .36). Early patient discontinuations
(25.9% fentanyl vs 25.0% morphine; P = .78) and last
pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P = .45) were not different between the 2 treatments. With continued
treatment for up to 48 or 72 hours, more than 80% of patient assessments in
each treatment group were good or excellent. The incidence of opioid-related
adverse events was similar between the groups.
Conclusion An investigational PCA transdermal system using iontophoresis to deliver
fentanyl provided postsurgical pain control equivalent to that of a standard
intravenous morphine regimen delivered by a PCA pump.
Patient-controlled analgesia (PCA) allows the patient to self-administer
small doses of opioids, such as fentanyl, morphine, hydromorphone, or meperidine,
as needed to manage pain. A key principle of PCA use is that it is initiated
after titration to patient comfort with loading doses of intravenous (IV)
opioids.1 Thereafter, PCA is used to maintain
a mild level of pain rather than total pain relief, allowing the patient to
self-administer enough drug to achieve a comfortable balance between analgesia
and adverse effects.2-5 Existing
PCA therapies infuse opioid analgesics through an IV line at a preset rate
by electronic pumps or by disposable, fixed-volume devices when a patient
activates a dosing button. Problems that compromise patient safety, such as
programming errors, uncontrolled delivery of syringe contents, and patient
tampering, have been reported.6 Pump failures
and syringe mix-ups are also possible.
To overcome these problems, a fentanyl hydrochloride patient-controlled
transdermal system (PCTS) is under development as an alternative method that
delivers small doses of fentanyl by iontophoresis with electrotransport delivery
platform technology (E-TRANS; ALZA Corp, Mountain View, Calif). The system
uses a low-intensity direct current to move fentanyl from a hydrogel reservoir
into the skin, where it then diffuses into the local circulation and is transported
to the central nervous system. The self-adhesive unit, about the size of a
credit card, is worn on the patient's upper arm or chest, does not have the
IV tubing, cables, and large pump of the IV PCA, and may facilitate patient
mobility. The opioid analgesic fentanyl has a potential advantage over morphine
in that it does not have active metabolites that can accumulate over time.7
For these advantages to be realized, the delivery method must provide
pain control that is comparable to that of current standard therapy. The purpose
of this study was to establish that the transdermal PCA delivery system is
equivalent to a standard morphine IV PCA regimen in postoperative pain management.
A prospective, randomized, parallel-group, unblinded, active-controlled
study was conducted from September 2000 to March 2001 at 29 US and 4 Canadian
hospitals. Centers were recruited according to the knowledge of postoperative
pain management of the local investigator and the proven ability of staff
to conduct research. The institutional review board, research ethics board,
or an independent centralized ethics review board approved the protocol. Patients
provided signed informed consent during the screening process.
A randomization schedule was created with computer-generated random
numbers in a block size of 4 by using all patients, regardless of center.
The patients were stratified by type of surgery (stratum 1: orthopedic, upper
abdominal, and thoracic; stratum 2: all other procedures, including lower
abdominal). Separate lists were generated for each stratum. The randomization
was developed to eliminate any bias on the part of the investigators and their
staff and to balance the number of patients between the 2 treatments and the
surgery types. Eligible patients were assigned a study treatment (fentanyl
PCTS or IV PCA morphine) with an interactive voice response system randomization
procedure.8 The investigators and their staff
did not know the block size or the next treatment assignment before randomization.
The fentanyl hydrochloride PCTS is manufactured to function within preset
dosing specifications. It operates for 24 hours after the first dose is delivered
or delivers a maximum of 80 doses and shuts off. The dose, controlled by the
amount of electrical current, is fixed to not exceed 40 µg, the dosing
interval is 10 minutes, and each dose is a 10-minute infusion. Drug delivery
begins when the electrical current is activated by pressing the dosing button
twice within 3 seconds. During delivery of the dose, the fentanyl PCTS cannot
deliver additional doses, and delivery of the dose cannot be interrupted or
The system provides an audible (beep) and visual indication (red light
from a light-emitting diode) that a dose has begun. The light turns off momentarily
when the dose has been completed and then flashes to indicate the approximate
number of doses delivered. One flash represents delivery of 1 to 5 doses,
2 flashes represent delivery of 6 to 10 doses, and so on. Because the maximum
number of doses allowed by the system is 80, the corresponding maximum number
of flashes is 16. Alerts for nonfunctioning conditions are a short series
of beeps (the fentanyl PCTS should be restarted) and continuous beeping (the
system has shut down and should be removed). Thus, the audible and visual
signals provide information on dosing similar to that of standard IV PCA.
The PCA pumps were programmed to deliver a 1-mg dose as a bolus, with
a subsequent 5-minute lockout and a limit of 10 doses per hour (10 mg). The
choice of the active comparator regimen is supported by the research of Owen
and colleagues,9 who showed an optimal balance
between efficacy and adverse effects at an on-demand morphine dose of 1 mg
compared with on-demand doses of 0.5 and 2 mg and using a dosing interval
of 5 minutes. Ginsberg et al10 demonstrated
similar efficacy for PCA regimens incorporating various lockout periods from
2 to 8 minutes. Because of the confounding logistics—patients would
have to press 2 dosing buttons simultaneously—the study was not blinded,
which would have required an IV PCA pump and a fentanyl PCTS for each patient.
Names of prospective participants were selected from hospital surgical
schedules. The patients were approached by anesthesiologists or surgeons to
ascertain interest in joining the study. Patients (N = 726) were screened
within 2 weeks before enrollment, written informed consent was obtained, and
medical history and a physical examination were conducted. Patients were instructed
in the use of the fentanyl PCTS and IV PCA morphine pump and in the performance
of the study assessments. Patients were aged at least 18 years; were American
Society of Anesthesiologists physical status I, II, or III (no, mild to moderate,
or severe systemic disturbance, respectively); were scheduled to undergo general
or regional anesthesia for major abdominal, orthopedic, or thoracic surgery;
and were expected to have moderate or severe pain requiring parenteral opioids
for at least 24 hours after surgery.
Postoperative screening occurred when patients were admitted to the
postanesthesia care unit (PACU; recovery room) after having undergone surgery.
They were awake and breathing spontaneously, with a respiratory rate of 8/min
to 24/min, arterial oxygen saturation by pulse oximetry (SpO2)
of at least 90% (with or without supplemental oxygen), able to answer questions
and follow commands, and had been in the PACU for at least 30 minutes and
were comfortable or had been brought to comfort with bolus IV doses of allowed
Patients (Figure 1) were excluded
because they had received a long-lasting intraoperative regional analgesic
or long-lasting intraspinal opioids, were expected to have postoperative analgesia
supplied by a continuous regional technique, or were expected to require intensive
care or would probably require additional surgical procedures within 36 hours.
Postoperative patients were also excluded if they had received intraoperative
or postoperative administration of opioids other than morphine, fentanyl,
sufentanil, or alfentanil (except up to 50 mg of meperidine for shivering),
were intubated at final screening assessments, were known or suspected to
be opioid tolerant, had a recent history of opioid dependence, or had active
systemic skin disease or active local skin disease that would preclude fentanyl
PCTS application to their arms or chest. Pregnant women or patients with coexisting
medical conditions likely to interfere with study procedures were not enrolled.
After surgery, patients were brought to the PACU and evaluated for the
remainder of the study entry criteria (vital signs, general postsurgical condition).
Patients were titrated to an acceptable level of comfort if needed with IV
doses of morphine, fentanyl, sufentanil, or alfentanil. After patients had
been in the PACU at least 30 minutes and were awake, alert, and comfortable,
they marked their pain intensity on a 100-mm visual analog scale (VAS), and
study staff recorded vital signs and SpO2. These assessments completed
the study entry criteria. Qualifying patients were then randomized in a 1
to 1 ratio to fentanyl PCTS or IV PCA morphine pump within each stratum as
defined by surgery type.
Pain intensity, vital signs, and oxygen saturation were assessed again,
and the time of this second set of assessments was the start of the treatment
period, hour 0. Immediately, the fentanyl PCTS was applied or the IV PCA morphine
pump was attached and enabled, and the patient was considered to be enrolled
(n = 636; Figure 1). The patient
was again instructed about use of the PCA. Only the patient was to deliver
a dose of fentanyl or morphine. Supplemental medication (single or multiple
IV bolus doses of fentanyl [fentanyl PCTS group] or morphine [IV PCA morphine
group]) was available on request during the first 3 hours after hour 0. Study
measurements (vital signs, oximetry, number of doses delivered, pain intensity
scores by VAS) were taken at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after enrollment
and every 4 hours thereafter up to 72 hours. Sleeping patients were not awakened
for pain assessments. Patient global assessments were obtained at 24, 48,
and 72 hours or when the patient discontinued study medication, whichever
came first. At any time in the study, patients who could not maintain pain
relief at a comfortable level (with or without supplemental analgesia) were
withdrawn from the trial to receive higher doses or additional analgesics
to control their pain. Study staff monitored patients and recorded patient-reported
adverse events, their severity and relationship to study treatments, concomitant
medications, and assessments of erythema at the application site.
The patient global assessment at 24 hours was the primary efficacy end
point. It consisted of a categorical evaluation (poor, fair, good, excellent)
of the method of pain control. The patient was read aloud the following question
by the investigator's staff, and the response was recorded: "Overall, would
you rate this method of pain control during the last 24 hours as being poor,
fair, good, or excellent?" Assessments were also collected at 48- and 72-hour
points for patients who remained in the study. If the patient was withdrawn
from the study before any 24-hour point, the assessment was completed at withdrawal,
and this observation was carried forward to the next 24-hour point.
Pain intensity was measured on a 100-mm ungraded VAS that ranged from
"no pain" (0 mm) to "worst possible pain" (100 mm). If the patient was withdrawn
from the study before a 24-hour point, the pain-intensity measurement was
completed at withdrawal. Patients were instructed to "Rate the pain you have
at this time. On a scale of ‘no pain' to ‘worst possible pain,'
rate where you feel your pain is at this moment." The patient was to make
a vertical mark on a 100-mm ungraded horizontal line anchored by "no pain"
and "worst possible pain" to indicate the amount of pain he or she was experiencing.
If the patient was unable to make a mark, the investigator's staff marked
the line as directed by the patient. The number of patients whose pain control
was inadequate and who were withdrawn from the study was tabulated.
At specified times, the investigator's staff recorded the number of
light flashes displayed by the fentanyl PCTS, the number of bolus doses delivered
displayed on the IV PCA morphine pump, and the supplemental IV bolus doses
of fentanyl or morphine used. The fentanyl PCTS dose was estimated by using
5 times the number of flashes minus 2.
Respiratory rate was the primary measure of systemic safety. Clinically
relevant respiratory depression (CRRD) was defined as the simultaneous occurrence
of bradypnea (respiratory rate less than 8/min sustained for 1 minute) and
excessive sedation (the patient is not easily aroused). Clinically relevant
respiratory depression was treated by ensuring a patent airway and providing
supportive treatment to reestablish regular breathing (stimuli, IV naloxone).
The patient could remain in study after 1 episode but would be withdrawn from
study if 2 episodes occurred. Opioid analgesia was suspended until alertness
and other vital signs were normal.
Demographic and clinical variables were summarized according to treatment
group for all randomized patients. Depending on the nature of the variable,
either the 2-sample t test (numeric data) or χ2 test (categorical data) was used to compare treatment groups.
Treated patients were those who received fentanyl PCTS or IV PCA morphine
and completed a patient global assessment. For the efficacy analyses, patients
who completed at least 72 hours of treatment, did not require further parenteral
opioid analgesia, or were discharged from the hospital were considered to
have completed the study. Patients who required parenteral opioid analgesia
after 24 hours could continue in the study to a maximum of 72 hours of treatment.
The patient global assessment at 24 hours was the primary efficacy end
point. The primary efficacy analysis was the construction of a 2-sided 95%
confidence interval (CI) for the difference in success rate (proportion of
excellent/good) according to the 24-hour patient global assessment data between
the 2 treatment groups. The 2 treatments were considered therapeutically equivalent
if the 95% CI of the difference in success rate fell within ±10% according
to 2 one-sided tests with α = .025 and a maximum acceptable difference
All data from all centers and surgery types were pooled. Center was
not used as a stratification variable because of the large number of centers
required for patient enrollment. The mean of the last pain intensity score
during the 24-hour treatment period(s) was analyzed with a 2-way analysis
of variance model.
A sample size of 504 evaluable patients (252 patients in each treatment
group) was planned for this study to provide an 80% probability to demonstrate
the therapeutic equivalence in proportion between 2 treatments.
Of the 90 patients screened who did not enter the study, 82 did not
meet the screening criteria and 8 met the screening criteria but decided not
to enroll in the study (Figure 1).
Demographic values were similar between the 2 treatment arms (Table 1). The patients were predominantly female and white. The
average age of the patients was about 50 years. Surgical procedures were primarily
lower abdominal, with the majority represented by gynecologic surgery or orthopedic
surgery (predominantly lower extremity and spinal procedures).
The 316 patients in the fentanyl PCTS group and the 320 patients in
the IV PCA morphine group represent the patients in the intent-to-treat analyses
for efficacy and safety (Figure 1).
Of these treated patients, 82 (25.9%) withdrew early from fentanyl PCTS and
80 patients (25.0%) discontinued IV PCA morphine (P =
.78; Table 2). Withdrawals because
of inadequate analgesia were fewer but not statistically significant in the
IV PCA morphine group (10.3%) compared with the fentanyl PCTS group (15.2%; P = .07).
In the withdrawal category of "other," a statistically significantly
higher proportion of patients using IV PCA morphine (19 patients, 5.9%) discontinued
for this reason than patients using fentanyl PCTS (6 patients, 1.9%) (P = .009). The most common "other" reason for withdrawal
in both treatment groups was because the patient or investigator requested
use of or a transfer to analgesic medications disallowed according to protocol
Fentanyl hydrochloride PCTS and IV PCA morphine were therapeutically
equivalent according to the primary end point of global ratings of method
of pain control during the first 24-hour treatment period. The distribution
of patient ratings is displayed in Table
3; the overall distribution of the proportion of patients' ratings
of poor, fair, good, or excellent between the 2 treatments is not statistically
different (P>.10). The primary analysis was applied
to a combined rating of good and excellent, which was reported by 73.7% of
patients who received fentanyl PCTS and 76.9% of patients who received IV
PCA morphine. The between-treatment difference in the good/excellent rating
was –3.2% (95% CI, –9.9% to 3.5%; P =
.36), which met the predefined statistical criterion for equivalence. With
continued treatment for up to 48 or 72 hours, more than 80% of patient assessments
in each treatment group were good or excellent.
The mean of the last recorded pain intensity scores (assessed on a VAS
of 0-100) within the first 24 hours for all treated patients was also statistically
indistinguishable between treatments, supporting the equivalence of fentanyl
PCTS relative to IV PCA morphine (Table
4). These mean scores were 32.7 for the fentanyl PCTS group and
31.1 for the IV PCA morphine group (P = .45). The
pain intensity scores were also comparable at all assessed times during the
24 hours (Table 4), and the distribution
of pain scores between the treatment groups at 3 and 24 hours was similar
(Figure 2). The magnitude of these
scores reflected a level to which patients commonly titrate themselves with
Fentanyl hydrochloride PCTS dosing was qualitatively similar to IV PCA
morphine pump (Table 5). Patients
in both treatment groups administered more doses per hour during the first
6 hours than in the subsequent 66 hours. The amount of fentanyl (1244 µg)
and morphine (43.9 mg) was typical of reported opioid consumption during the
first 24 hours after major surgery.11 The percentage
of the maximum possible doses used during the entire 72-hour study period
was 22.0% for fentanyl PCTS and 17.2% for IV PCA morphine treatments. Supplemental
IV opioid was allowed during the first 3 hours after treatment initiation
to retitrate patients to comfort. Both groups were similar in that their pain
during the first 3 hours after treatment initiation required administration
of supplemental analgesic to establish comfort. The proportion of patients
who received supplemental IV opioid was similar for both treatment groups
The incidence of opioid-related adverse events was similar between the
fentanyl PCTS and IV PCA morphine groups (Table 6). Other opioid-related adverse events that occurred less
frequently in the PCTS group and IV PCA group were hypotension (1.3%, 1.9%,
respectively), urinary retention (1.6%, 0.6%), hypoventilation (0.3%, 1.3%),
and ileus (0.9%, 0.6%). Adverse events, most of which were considered treatment-related,
led to early discontinuations for 6% of patients per treatment group (Table 2). Two of 29 serious adverse events
reported for 21 patients were considered to be related to study medication:
a report of severe confusion that prolonged hospitalization was attributed
to fentanyl PCTS treatment, and a report of CRRD was attributed to IV PCA
morphine treatment. The CRRD was reported as a respiratory adverse event (4/min,
moderate sedation). The patient was given naloxone and was withdrawn from
the study. No patient who received fentanyl PCTS developed CRRD.
Application site reactions (6.3%) reported as spontaneous adverse events
by fentanyl PCTS patients were mild to moderately severe in all but 1 case.
Scheduled skin evaluations at 24 hours after system removal revealed erythema
in approximately half (53.8%) of the fentanyl PCTS patients. Most of this
erythema was mild, resembling sunburn or tanning marks. None required treatment,
and all resolved within 4 weeks.
The fentanyl hydrochloride PCTS provided PCA after major surgery that
was therapeutically equivalent to a standard IV PCA morphine regimen, as judged
by patient global assessments, the predefined primary end point. The other
efficacy variables—pain intensity scores and discontinuation for inadequate
analgesia—confirmed the primary efficacy variable. Within the subset
of patients who withdrew for inadequate analgesia, more patients were in the
fentanyl PCTS group (15.2%) compared with the IV PCA group (10.3%; Table 2). However, pain intensity scores
of the 2 treatments were comparable at each assessment (Table 4), and the dosing pattern of the 2 treatments with respect
to frequency of dosing over time and the proportion of total available doses
activated was similar (Table 5).
These data do not reveal a reason for the different withdrawal rate. Eight
patients in the IV PCA group withdrew from the study to use study-prohibited
analgesics compared with 2 in the fentanyl PCTS group (Table 2). It is possible that these patients should have been attributed
to withdrawal for inadequate analgesia.
Individualized dosing with PCA addresses the subjective nature of a
patient's ability to tolerate pain and his or her requirement for and response
to opioids. PCA is initiated when patients have been made comfortable. For
postoperative patients, this initiation generally occurs after administration
of loading doses of IV opioids,7 which results
in large interpatient variation (up to 5-fold) in plasma concentrations associated
with analgesic efficacy.7 Therefore, PCA delivery
systems are ideally suited to provide safe and effective individualized treatment
of acute pain, allowing self-titration in small-dose increments to maintain
The safety and efficacy of PCA with systemic opioids in the postoperative
setting in general and with fentanyl specifically have been widely reported
for nearly 20 years, at doses ranging from 10 to 60 µg and lockout intervals
ranging from 1 to 10 minutes.1,3-5,10,12-14 Fentanyl
is considered to have 50 to 100 times the potency of morphine according to
responses to IV bolus doses.15 With this conversion
factor, the average amount of fentanyl accessed by patients in the first 24
hours of this study (1244 µg) would be equivalent to 62 to 124 mg morphine,
which exceeds the amount of morphine (43.9 mg) accessed by IV PCA patients
(Table 5). This discontinuity
may be because the number of fentanyl doses delivered is estimated within
a 1- to 5-dose range by observing the number of dosing flashes from the fentanyl
PCTS, and the pharmacodynamic actions of a 10-minute infusion of 40 µg
of fentanyl may be different than an IV bolus of 40 µg of fentanyl.7 The 40-µg dose for the PCTS was selected after
the study by Camu et al14 in which a 10-minute
infusion of 40 µg yielded an optimal profile of pain relief and safety
compared with infusions of 20 or 60 µg of fentanyl.
The inherent safety of PCA is that the dosing frequency is controlled
as needed by the patient for pain relief, reducing the possibility of overdose
as pain requirements are met. A meta-analysis of 15 randomized controlled
studies showed that postoperative patients using PCA obtained significantly
better pain relief than those using intramuscular analgesia, with no increase
in adverse effects.16 The study also showed
that patients using PCA in this setting tended to use less total opioid and
had shorter hospital stays, although this trend was not statistically significant.
The Acute Pain Management Panel, in its Clinical Practice
Guideline for acute pain management,17 also
notes that for patients who have had thoracic surgery, PCA results in incrementally
improved analgesia, increased patient satisfaction, and trends toward improved
pulmonary function and earlier recovery or discharge compared with intramuscular
or bolus IV injections.
Building on the PCA concept that has become the standard of care in
many facilities for the management of postoperative and other acute pain,
fentanyl PCTS was designed to provide a preprogrammed, self-contained, noninvasive
alternative to IV PCA. Key system design characteristics, the choice of the
40-µg dose on demand, the 10-minute dosing interval, and the 80-dose
maximum available from each system, were carefully selected according to the
substantial literature in this field and corroborated in phase 1 and 2 clinical
trials.12,14 The fentanyl PCTS
does not incorporate a continuous infusion with the on-demand bolus doses
because previous studies indicate that a continuous basal infusion does not
enhance efficacy during acute use.6,7 This
integrated drug-device delivery system incorporates design features that effectively
prevent unintentional dosing during use, such as a recessed dosing button,
double-push activation, and electronic lockout and disablement features.
Limitations of this study are the open design and lack of placebo control.
The study was not blinded, because patients would have been required to push
the buttons of the pump and transdermal PCA system simultaneously when seeking
pain medication and would shortly have determined which delivery system contained
opioid. Randomized, blinded, placebo-controlled trials have been conducted
that demonstrate the superiority of the fentanyl PCTS for pain control compared
with a PCTS that did not deliver fentanyl.18
Another limitation is that no single morphine IV PCA regimen is "approved"
for postoperative analgesia, and the morphine IV PCA regimen chosen for this
study was a fixed dose, whereas physicians tend to think of IV PCA as adjustable.
Although current IV PCA pumps allow a wide variety of dosing regimens, the
preferred doses reported in the literature are similar.6 In
practice, clinicians seldom deviate from a narrow dose range similar to those
used in this study. Patients with extreme opioid requirements may require
a customized regimen, but this is the exception. For example, fentanyl PCTS
may not be appropriate for opioid-tolerant patients whose opioid dose requirement
may be higher than that provided by the system. The fentanyl PCTS may also
be criticized for lack of programming flexibility, but this feature would
introduce the risk of programming errors and dosing mistakes.6 In
addition, current approaches for acute pain management use adjuvant analgesics
such as regional blocks, wound infiltration, or systemic nonsteroidal anti-inflammatory
drugs with PCA.19 Future fentanyl PCTS studies
will need to address its use in a multimodal analgesic setting.
An investigational PCA transdermal system using iontophoresis to deliver
fentanyl provided postsurgical pain control equivalent to that of standard
IV morphine delivered by a PCA pump. The PCTS offers the advantages of needle-free,
preprogrammed operation in a small, self-contained unit.
Create a personal account or sign in to: